Secondly, there are encouraging data on ADCs targeting Trop-2, specifically sacituzumab govitecan, which has shown positive results in terms of response and survival in endometrioid and serous subtypes of endometrial cancer where Trop2 is more commonly expressed [87]. The gene discussed is TACSTD2; the disease is endometrial cancer.